Tandem Diabetes Care TNDM Payments to Acquire in Process Research and Development

Other financials

Revenue$247.2M+5.5%

Gross profit$136.8M+15.5%

Operating income-$17.4M+85.6%

Net income-$20.4M+84.4%

EPS (diluted)-$0.30+84.8%

Cash & equivalents$179.3M+235%

Total debt$734.7M+49.0%

Total equity$132.4M-14.7%

Total assets$1.2B+25.1%

Operating cash flow$11.1M+160%

CapEx$6.3M+111%

Free cash flow$4.8M+123%

Market cap$1.08B-19.8%

Enterprise value$1.64B-8.5%

P/S1.1×-0.3×

Gross margin54.9%+2.7pp

Operating margin-8.2%-2.9pp

Net margin-9.2%-3.1pp

FCF margin-0.8%-0.4pp

Return on equity-65.7%-14.7pp

Debt / equity5.5×+2.4×

Current ratio3.6×+1.3×

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Tandem Diabetes Care's payments to acquire in process research and development?: Tandem Diabetes Care (TNDM) reported payments to acquire in process research and development of $0 in Q1 2026.
How has Tandem Diabetes Care's payments to acquire in process research and development changed year-over-year?: Tandem Diabetes Care's payments to acquire in process research and development decreased by 100.0% year-over-year, from $43.46M to $0.